Evolutionary biology of high-risk multiple myeloma
The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …
driven by treatment advances. However, there is a subset of patients considered to have …
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Understanding the profile of oncogene and tumor suppressor gene mutations with their
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …
The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma
Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple
different initiating events. A recent multi-region sequencing study demonstrated spatial …
different initiating events. A recent multi-region sequencing study demonstrated spatial …
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
S Skerget, D Penaherrera, A Chari, S Jagannath… - Nature Genetics, 2024 - nature.com
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of
plasma cells characterized by diverse and complex tumor genetics for which precision …
plasma cells characterized by diverse and complex tumor genetics for which precision …
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes
as well as patient factors that impact the capacity to deliver treatment. How the relative …
as well as patient factors that impact the capacity to deliver treatment. How the relative …
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
L Rasche, EJ Angtuaco, TL Alpe… - Blood, The Journal …, 2018 - ashpublications.org
Spatial intratumor heterogeneity is frequently seen in multiple myeloma (MM) and poses a
significant challenge for risk classifiers, which rely on tumor samples from the iliac crest …
significant challenge for risk classifiers, which rely on tumor samples from the iliac crest …
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
Background The tumor microenvironment (TME) is increasingly appreciated as an important
determinant of cancer outcome, including in multiple myeloma (MM). However, most …
determinant of cancer outcome, including in multiple myeloma (MM). However, most …
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
KRAS, NRAS, and BRAF mutations which activate p44/42 mitogen-activated protein kinase
(MAPK) signaling are found in half of myeloma patients and contribute to proteasome …
(MAPK) signaling are found in half of myeloma patients and contribute to proteasome …
What is the future of immunotherapy in multiple myeloma?
L Rasche, M Hudecek, H Einsele - Blood, The Journal of the …, 2020 - ashpublications.org
The treatment of multiple myeloma (MM) is currently being redefined by humoral and cellular
immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy …
immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy …
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of multiple myeloma
(MM) that is characterized by the presence of≥ 20% circulating plasma cells. Overall …
(MM) that is characterized by the presence of≥ 20% circulating plasma cells. Overall …